Form 4: Cabaletta Bio Executive Gwendolyn Binder Receives Repriced Stock Options

Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., received repriced stock options effective May 19, 2025, as approved by the board of directors.

Summary

• Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 19, 2025, Ms. Binder received repriced stock options as part of a board-approved repricing plan.
• The repricing affected multiple stock option awards with varying original exercise prices and expiration dates.
• The new exercise price for the repriced options is $1.92 per share, reflecting the fair market value on the repricing date.
• A retention period is in effect, where the options revert to their original exercise price if exercised within one year of the repricing date, upon a sale event, or termination of service due to death or disability.

Sentiment

Score: 6

Explanation: The document itself is neutral, detailing a routine executive compensation adjustment. The impact on the company is likely to be moderately positive, as it incentivizes a key executive.

Positives

• The repricing of stock options may incentivize Ms. Binder to remain with the company and contribute to its success.
• The new exercise price of $1.92 aligns the options with the current fair market value of Cabaletta Bio's common stock.

Risks

• If Ms. Binder leaves the company or a sale event occurs within one year, the options could revert to their original, potentially higher, exercise prices.
• The repricing could be perceived negatively by shareholders if it is seen as excessively rewarding management.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the stock option repricing and vesting schedule.

Industry Context

Option repricing is a tool companies use to re-incentivize employees when the stock price has fallen below the option's exercise price. It's common in the biotech industry, which can be volatile.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, particularly in volatile sectors like biotechnology.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation packages.
• The specific terms of the repricing, such as the retention period, are typical features designed to ensure continued service.

Stakeholder Impact

• Shareholders may view the repricing as a positive incentive for management or as a potential dilution of equity.
• Employees may see the repricing as a positive sign of the company's commitment to its employees.

Key Dates

Keywords

stock options, Cabaletta Bio, Gwendolyn Binder, repricing, Form 4, beneficial ownership, executive compensation